<ul>
<li>药明康德（Catalyst Pharmaceuticals），股票代码 NasdaqCM:CPRX，已同意以全现金交易方式被 Angelini Pharma 收购。</li>
<li>公司已解决所有待决的 Firdapse 专利诉讼，并授予有效期至 2035 年的仿制药许可证。</li>
<li>此交易标志着当前公众股东的退出，并将重塑药明康德在罕见疾病药物市场的运营方式。</li>
</ul>
<p>药明康德专注于罕见神经疾病的治疗，Firdapse 是其关键产品。Angelini Pharma 的全现金收购以及 Firdapse 专利争议的解决，恰逢许多大型医疗集团对罕见疾病药物保持核心关注。对于您作为股东或行业观察者而言，这些举措将 NasdaqCM:CPRX 的故事从独立增长转变为融入更大制药集团的整合。</p>
<p>长期的 Firdapse 仿制药许可证框架有效期至 2035 年，为该产品的竞争发展提供了更清晰的视角。关注 NasdaqCM:CPRX 的投资者现在可能会更加关注交易条款、预计的完成时间表，以及合并后的业务在交易完成后如何定位其罕见疾病产品组合。</p>
<p>通过将药明康德添加到您的关注列表或投资组合中，随时了解药明康德最重要的新闻故事。或者，探索我们的社区，发现关于药明康德的新视角。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c52b3e44-8ab3-4c21-8642-d3074664ed08/chart/earnings-and-revenue-growth/query-ZGF0ZT0yMDI2LTA1LTE3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c52b3e44-8ab3-4c21-8642-d3074664ed08/chart/earnings-and-revenue-growth/query-ZGF0ZT0yMDI2LTA1LTE3"/></p>
<p>截至 2026 年 5 月的 NasdaqCM:CPRX 收益与收入增长</p>
<p>药明康德的三件好事，这个标题没有提到。</p>
<p>Angelini Pharma 的全现金交易有效地为公众股东提供了一个明确的退出价格，同时将药明康德的罕见疾病产品组合置于一个更大的欧洲总部制药集团内。对于您而言，短期关注点从 Firdapse、Agamree 或 Fycompa 的季度变动转向交易完成的可能性和时间，因为公司预计在交易完成后将被退市。所有 Firdapse 专利争议的解决，以及根据协议 Hetero 在美国的仿制药进入预计不早于 2035 年 1 月，消除了之前与一款旗舰药物的收入集中相关的关键法律隐患。结合 2026 年第一季度 1.4939 亿美元的收入和 6373 万美元的净收入，该业务在报告盈利运营的同时被收购。对于 Angelini Pharma 来说，该产品组合在罕见神经疾病领域增加了规模，并扩大了在美国市场的覆盖面，Biogen、UCB 和 Jazz Pharmaceuticals 等集团也在该市场活跃。对于当前股东而言，仍需清除的一系列条件包括股东批准、监管和反垄断签署，以及融资方案的实际执行。</p>
<h3>这如何融入药明康德的叙述</h3>
<ul>
<li>收购和 Firdapse 诉讼和解与强调持久利润、现金生成和业务发展的叙述一致，作为扩大罕见疾病产品组合的方式。</li>
<li>出售公司的举动可能会挑战市场对药明康德将继续利用其资产负债表和现金流进行独立产品发布和收购的预期。</li>
<li>39 亿美元的全现金交易和同意的仿制药许可证有效期至 2035 年，并未完全反映在早期围绕开放式专利风险和可能的仿制药竞争时间的讨论中。</li>
</ul>
<p>了解一家公司的价值始于理解其故事。查看 Simply Wall St 社区中药明康德的顶级叙述，以帮助您决定其对您的价值。</p>
<h3>投资者应考虑的风险与回报</h3>
<ul>
<li>⚠️ 如果股东未批准交易、监管机构提出担忧，或融资和惯例条件未满足，交易可能无法完成。这可能导致股票在没有确认收购价格的支持下交易。</li>
<li>⚠️ 即使 Firdapse 专利诉讼已解决，并且当前对手方的许可证有效期至 2035 年，药明康德仍面临产品集中风险，如果未来在类似适应症中的疗法减少了对其关键药物的需求。</li>
<li>🎁 每股 31.5 美元的全现金对价清晰地表明了 Angelini Pharma 愿意为药明康德当前的盈利状况和罕见疾病产品组合支付的价值。</li>
<li>🎁 解决所有待决的 Firdapse 专利诉讼消除了核心资产的法律不确定性，这可能简化您对该产品在约定的仿制药许可证期间现金流的思考。</li>
</ul>
<h3>未来关注事项</h3>
<p>从这里开始，关注 2026 年第三季度的预计关闭时间表的进展，包括股东投票日期、监管备案以及关于反垄断审查的任何评论，都是有意义的。相对于每股 31.5 美元的报价，交易差价也可以为您提供对完成风险的市场评估。在运营方面，Firdapse、Agamree 及更广泛产品组合的季度销售更新仍然相关，因为它们影响双方在任何重新谈判或竞争利益出现时对业务的看法。最后，关注 Angelini Pharma 关于整合计划的任何披露，特别是它打算如何将药明康德的产品与 Biogen、UCB 和 Jazz Pharmaceuticals 等竞争对手在罕见神经和癫痫相关疾病中的产品进行定位。</p>
<p>为了确保您始终了解最新消息如何影响药明康德的投资叙述，请访问药明康德的社区页面，以便不错过关于顶级社区叙述的更新。</p>
<p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章不应被视为财务建议。</strong> 它不构成买卖任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>
<h3><strong>新功能：</strong> AI 股票筛选器与警报</h3>
<p>我们的新 AI 股票筛选器每天扫描市场以发现机会。</p>
<p>• 分红强劲的公司（收益率 3% 以上）</p>
<p>• 内部人士购买的被低估小盘股</p>
<p>• 高增长的科技和 AI 公司</p>
<p>或者从 50 多个指标中构建您自己的筛选器。</p>
<p>立即免费探索</p>

触媒制药公司

<p>催化剂制药公司（NasdaqCM: CPRX）已同意被 Angelini Pharma 以全现金方式收购，解决了 Firdapse 专利诉讼，并授予了直到 2035 年的仿制药许可证。此交易标志着催化剂从独立增长转向融入更大制药集团，为股东提供了明确的退出方案。此次收购的估值为 39 亿美元，预计将在 2026 年第三季度完成，待股东和监管机构的批准。投资者应关注交易的进展以及催化剂产品组合的表现</p>

<ul>
<li>Catalyst Pharmaceuticals, ticker NasdaqCM:CPRX, has agreed to be acquired by Angelini Pharma in a definitive all cash transaction.</li>
<li>The company has settled all pending Firdapse patent litigation, granting generic licenses that run through 2035.</li>
<li>The deal marks an exit for current public shareholders and is set to reshape how Catalyst Pharmaceuticals operates within the rare disease drug market.</li>
</ul>
<div class="lb-trans"><ul>
<li>药明康德（Catalyst Pharmaceuticals），股票代码 NasdaqCM:CPRX，已同意以全现金交易方式被 Angelini Pharma 收购。</li>
<li>公司已解决所有待决的 Firdapse 专利诉讼，并授予有效期至 2035 年的仿制药许可证。</li>
<li>此交易标志着当前公众股东的退出，并将重塑药明康德在罕见疾病药物市场的运营方式。</li>
</ul>
</div><p>Catalyst Pharmaceuticals focuses on treatments for rare neurological conditions, with Firdapse as a key product. The all cash acquisition by Angelini Pharma and the resolution of Firdapse patent disputes arrive at a time when rare disease drugs remain a core area of interest for many large healthcare groups. For you as a shareholder or sector watcher, these moves change the story around NasdaqCM:CPRX from independent growth to integration within a larger pharmaceutical group.</p>
<div class="lb-trans"><p>药明康德专注于罕见神经疾病的治疗，Firdapse 是其关键产品。Angelini Pharma 的全现金收购以及 Firdapse 专利争议的解决，恰逢许多大型医疗集团对罕见疾病药物保持核心关注。对于您作为股东或行业观察者而言，这些举措将 NasdaqCM:CPRX 的故事从独立增长转变为融入更大制药集团的整合。</p>
</div><p>The long term generic licensing framework on Firdapse through 2035 provides a clearer view of how competition around this product may develop. Investors following NasdaqCM:CPRX may now pay closer attention to the transaction terms, the expected timeline to closing, and how the combined business could position its rare disease portfolio after the deal completes.</p>
<div class="lb-trans"><p>长期的 Firdapse 仿制药许可证框架有效期至 2035 年，为该产品的竞争发展提供了更清晰的视角。关注 NasdaqCM:CPRX 的投资者现在可能会更加关注交易条款、预计的完成时间表，以及合并后的业务在交易完成后如何定位其罕见疾病产品组合。</p>
</div><p>Stay updated on the most important news stories for Catalyst Pharmaceuticals by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Catalyst Pharmaceuticals.</p>
<div class="lb-trans"><p>通过将药明康德添加到您的关注列表或投资组合中，随时了解药明康德最重要的新闻故事。或者，探索我们的社区，发现关于药明康德的新视角。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c52b3e44-8ab3-4c21-8642-d3074664ed08/chart/earnings-and-revenue-growth/query-ZGF0ZT0yMDI2LTA1LTE3" alt="" original-src="https://images.simplywall.st/company/c52b3e44-8ab3-4c21-8642-d3074664ed08/chart/earnings-and-revenue-growth?date=2026-05-17"/></p>
<p>NasdaqCM:CPRX Earnings &amp; Revenue Growth as at May 2026</p>
<div class="lb-trans"><p>截至 2026 年 5 月的 NasdaqCM:CPRX 收益与收入增长</p>
</div><p>3 things going right for Catalyst Pharmaceuticals that this headline doesn't cover.</p>
<div class="lb-trans"><p>药明康德的三件好事，这个标题没有提到。</p>
</div><p>The Angelini Pharma all cash deal effectively gives public shareholders a defined exit price while placing Catalyst’s rare disease portfolio inside a larger European headquartered pharmaceutical group. For you, the near term focus shifts from quarterly moves in Firdapse, Agamree or Fycompa to the likelihood and timing of deal completion, because the company is expected to be delisted once the transaction closes. The settlement of all Firdapse patent disputes, with generic entry in the United States not expected before January 2035 for Hetero under the agreement, removes a key legal overhang that previously sat alongside revenue concentration in one flagship drug. Combined with Q1 2026 revenue of US$149.39 million and net income of US$63.73 million, the business is being acquired while it is reporting profitable operations. For Angelini Pharma, the portfolio adds scale in rare neurological diseases and expands reach in the US market, where groups such as Biogen, UCB and Jazz Pharmaceuticals are also active. For current shareholders, the set of conditions that still needs to be cleared includes stockholder approval, regulatory and antitrust sign offs, and the practical execution of the financing package.</p>
<div class="lb-trans"><p>Angelini Pharma 的全现金交易有效地为公众股东提供了一个明确的退出价格，同时将药明康德的罕见疾病产品组合置于一个更大的欧洲总部制药集团内。对于您而言，短期关注点从 Firdapse、Agamree 或 Fycompa 的季度变动转向交易完成的可能性和时间，因为公司预计在交易完成后将被退市。所有 Firdapse 专利争议的解决，以及根据协议 Hetero 在美国的仿制药进入预计不早于 2035 年 1 月，消除了之前与一款旗舰药物的收入集中相关的关键法律隐患。结合 2026 年第一季度 1.4939 亿美元的收入和 6373 万美元的净收入，该业务在报告盈利运营的同时被收购。对于 Angelini Pharma 来说，该产品组合在罕见神经疾病领域增加了规模，并扩大了在美国市场的覆盖面，Biogen、UCB 和 Jazz Pharmaceuticals 等集团也在该市场活跃。对于当前股东而言，仍需清除的一系列条件包括股东批准、监管和反垄断签署，以及融资方案的实际执行。</p>
</div><h3>How This Fits Into The Catalyst Pharmaceuticals Narrative</h3>
<div class="lb-trans"><h3>这如何融入药明康德的叙述</h3>
</div><ul>
<li>The acquisition and the Firdapse litigation settlement are consistent with a narrative that emphasises durable margins, cash generation and business development as a way to grow a rare disease portfolio.</li>
<li>The move to sell the company may challenge expectations that Catalyst would keep using its balance sheet and cash flows to pursue independent product launches and acquisitions over many years.</li>
<li>The definitive US$3.9b all cash deal and the agreed generic licences through 2035 are not fully reflected in earlier narrative discussions that centred on open ended patent risk and the timing of possible generic competition.</li>
</ul>
<div class="lb-trans"><ul>
<li>收购和 Firdapse 诉讼和解与强调持久利润、现金生成和业务发展的叙述一致，作为扩大罕见疾病产品组合的方式。</li>
<li>出售公司的举动可能会挑战市场对药明康德将继续利用其资产负债表和现金流进行独立产品发布和收购的预期。</li>
<li>39 亿美元的全现金交易和同意的仿制药许可证有效期至 2035 年，并未完全反映在早期围绕开放式专利风险和可能的仿制药竞争时间的讨论中。</li>
</ul>
</div><p>Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Catalyst Pharmaceuticals to help decide what it's worth to you.</p>
<div class="lb-trans"><p>了解一家公司的价值始于理解其故事。查看 Simply Wall St 社区中药明康德的顶级叙述，以帮助您决定其对您的价值。</p>
</div><h3>The Risks and Rewards Investors Should Consider</h3>
<div class="lb-trans"><h3>投资者应考虑的风险与回报</h3>
</div><ul>
<li>⚠️ The deal may not close if stockholders do not approve it, if regulators raise concerns, or if financing and customary conditions are not satisfied. This could leave the stock trading without the support of a confirmed takeout price.</li>
<li>⚠️ Even with Firdapse patent litigation settled and licences set through 2035 for current counterparties, Catalyst still carries product concentration risk if future therapies in similar indications reduce demand for its key drugs.</li>
<li>🎁 The all cash consideration of US$31.5 per share provides clarity on the value Angelini Pharma is willing to pay for Catalyst’s current earnings profile and rare disease portfolio.</li>
<li>🎁 Resolving all pending Firdapse patent litigation removes legal uncertainty around a core asset, which may simplify how you think about cash flows from that product through the agreed generic licence period.</li>
</ul>
<div class="lb-trans"><ul>
<li>⚠️ 如果股东未批准交易、监管机构提出担忧，或融资和惯例条件未满足，交易可能无法完成。这可能导致股票在没有确认收购价格的支持下交易。</li>
<li>⚠️ 即使 Firdapse 专利诉讼已解决，并且当前对手方的许可证有效期至 2035 年，药明康德仍面临产品集中风险，如果未来在类似适应症中的疗法减少了对其关键药物的需求。</li>
<li>🎁 每股 31.5 美元的全现金对价清晰地表明了 Angelini Pharma 愿意为药明康德当前的盈利状况和罕见疾病产品组合支付的价值。</li>
<li>🎁 解决所有待决的 Firdapse 专利诉讼消除了核心资产的法律不确定性，这可能简化您对该产品在约定的仿制药许可证期间现金流的思考。</li>
</ul>
</div><h3>What To Watch Going Forward</h3>
<div class="lb-trans"><h3>未来关注事项</h3>
</div><p>From here, it makes sense to watch progress against the stated closing timeline in the third quarter of 2026, including the stockholder vote date, regulatory filings and any commentary on antitrust review. Deal spreads relative to the US$31.5 per share offer price can also give you a market based read on perceived completion risk. On the operating side, quarterly updates on sales of Firdapse, Agamree and the broader portfolio remain relevant, because they influence how both parties view the business if any renegotiation or competing interest emerges. Finally, keep an eye on any disclosures about integration plans from Angelini Pharma, especially around how it intends to position Catalyst’s products against offerings from competitors such as Biogen, UCB and Jazz Pharmaceuticals in rare neurological and seizure related conditions.</p>
<div class="lb-trans"><p>从这里开始，关注 2026 年第三季度的预计关闭时间表的进展，包括股东投票日期、监管备案以及关于反垄断审查的任何评论，都是有意义的。相对于每股 31.5 美元的报价，交易差价也可以为您提供对完成风险的市场评估。在运营方面，Firdapse、Agamree 及更广泛产品组合的季度销售更新仍然相关，因为它们影响双方在任何重新谈判或竞争利益出现时对业务的看法。最后，关注 Angelini Pharma 关于整合计划的任何披露，特别是它打算如何将药明康德的产品与 Biogen、UCB 和 Jazz Pharmaceuticals 等竞争对手在罕见神经和癫痫相关疾病中的产品进行定位。</p>
</div><p>To ensure you're always in the loop on how the latest news impacts the investment narrative for Catalyst Pharmaceuticals, head to the community page for Catalyst Pharmaceuticals to never miss an update on the top community narratives.</p>
<div class="lb-trans"><p>为了确保您始终了解最新消息如何影响药明康德的投资叙述，请访问药明康德的社区页面，以便不错过关于顶级社区叙述的更新。</p>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章不应被视为财务建议。</strong> 它不构成买卖任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>
</div><h3><strong>New:</strong> AI Stock Screener &amp; Alerts</h3>
<div class="lb-trans"><h3><strong>新功能：</strong> AI 股票筛选器与警报</h3>
</div><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p>
<div class="lb-trans"><p>我们的新 AI 股票筛选器每天扫描市场以发现机会。</p>
</div><p>• Dividend Powerhouses (3%+ Yield)</p>
<div class="lb-trans"><p>• 分红强劲的公司（收益率 3% 以上）</p>
</div><p>• Undervalued Small Caps with Insider Buying</p>
<div class="lb-trans"><p>• 内部人士购买的被低估小盘股</p>
</div><p>• High growth Tech and AI Companies</p>
<div class="lb-trans"><p>• 高增长的科技和 AI 公司</p>
</div><p>Or build your own from over 50 metrics.</p>
<div class="lb-trans"><p>或者从 50 多个指标中构建您自己的筛选器。</p>
</div><p>Explore Now for Free</p>
<div class="lb-trans"><p>立即免费探索</p>
</div>

Angelini 的收购以及 Firdapse 的和解重新定义了触媒制药公司的故事